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Abstract: The use of third-generation aromatase inhibitors (AIs), such as anastrozole and 
letrozole, as initial adjuvant hormonal therapy in postmenopausal women (PMW) with hormone 
receptor-positive (HR+) breast cancer offers a significant benefit over tamoxifen for reducing 
recurrence risk. Clinical studies, including the Arimidex Tamoxifen Alone or in Combination 
(ATAC) and the Breast International Group (BIG) 1-98 trials, have proven that both anastro-
zole and letrozole are, respectively, superior to tamoxifen in improving disease-free survival. 
Although differing in design, objectives, and follow-up time, these trials offer some insight into 
the comparative clinical efficacy of these two nonsteroidal AIs. In particular, results from BIG 
1-98 show that letrozole significantly reduces early distant metastatic (DM) events, which con-
stitute the majority of early recurrence events. Subsequently, there is a beneficial overall survival 
effect emerging in the trial, whereas survival is unchanged with anastrozole after 100 months 
of follow-up in ATAC. Significant differences in the potency of these two drugs, vis-à-vis their 
degree of aromatase inhibition, have been observed in comparative trials and show that letrozole 
causes a more complete suppression of estrogen levels than does anastrozole. Whether this 
difference in potency is relevant to reductions in DM events during adjuvant therapy remains 
unclear. The Femara Anastrozole Clinical Evaluation trial is addressing this issue in a more 
unequivocal manner by comparing initial adjuvant treatment with anastrozole or letrozole in 
a population of breast cancer patients at high risk of recurrence: PMW with HR+ disease and 
axillary lymph node involvement.
Keywords: anastrozole, aromatase inhibitors, hormone receptor-positive (HR+) breast cancer, 
letrozole, postmenopausal women, tamoxifen
Introduction
Adjuvant hormonal therapy remains an integral component of treatment for patients 
with hormone receptor-positive (HR+) early breast cancer, and antagonism of estrogen 
(E2) has been the foundation of treatments to reduce the risk of breast cancer recur-
rence. Most notable in this respect is the selective estrogen receptor (ER) modulator 
tamoxifen, which has been in use since the 1970s and has been proven to significantly 
reduce both breast cancer recurrence and death from breast cancer in patients with 
HR+, successfully resected disease.1 Tamoxifen acts via a competitive inhibition of 
E2 binding to the ER, thereby inhibiting the proliferative action of E2 in breast cancer 
cells. The drug also may act as an estrogen agonist in selected tissues such as the endo-
metrium, and has been associated with a number of adverse effects, including uterine 
cancer and thromboembolic events.2,3 In postmenopausal women (PMW), although 
ovarian E2 production has ceased, significant plasma levels of E2 may still exist via Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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peripheral conversion of androgens to E2, a process entirely 
dependent on the activity of the enzyme aromatase.4,5 There-
fore, aromatase has been a target of breast cancer therapy for 
PMW, and three generations of aromatase inhibitors (AIs) 
have been developed over the years.4–6 AIs are characterized 
into two types: steroidal aromatase inactivators, which bind 
irreversibly to the androstenedione binding site of aromatase, 
and nonsteroidal AIs, which bind in a reversible fashion to 
the heme component of aromatase.4–6 First-generation non-
steroidal AIs such as aminoglutethimide became available as 
early as the 1970s but were of limited use because of their 
nonselectivity and corresponding side-effect profiles, which 
included adrenal insufficiency, nausea, rash, somnolence, 
and blood dyscrasias.5,6 The second-generation nonsteroidal 
drug fadrozole also was suboptimal because of its effects 
on adrenal and mineralocorticoid hormone   suppression.5 
The third-generation nonsteroidal AIs anastrozole and letro-
zole, as well as the steroidal aromatase inactivator exemes-
tane, were approved for clinical use in the 1990s. All three 
of these drugs are highly selective for aromatase and show 
good oral bioavailability.4,5
In major clinical studies comparing initial adjuvant therapy 
between the third-generation AIs anastrozole or letrozole with 
tamoxifen, a significant benefit of AI treatment in reducing 
disease recurrence and improving disease-free survival (DFS) 
has been observed.7–12 Another trial has examined the efficacy 
of a switch to exemestane after 2 to 3 years of prior treatment 
with tamoxifen relative to continued tamoxifen treatment 
(switch adjuvant therapy); this trial also showed a benefit of 
AI therapy versus continued tamoxifen.13 Yet another trial has 
examined the use of letrozole relative to placebo after about 
5 years of tamoxifen therapy (extended adjuvant therapy).14 
These pivotal trials have led to the approval of AIs for use 
in these different treatment settings (ie, initial, switch, and 
extended adjuvant therapy). The nonsteroidal AIs anastrozole 
and letrozole, in particular, have been approved for use in 
the initial adjuvant setting and are significantly more effec-
tive than tamoxifen in improving DFS. Both drugs are also 
well tolerated, with predictable adverse event profiles that 
closely mimic changes associated with menopause, such as 
bone loss and arthralgias, but with lower incidences of other 
serious events, such as thromboembolic and gynecologic 
events, compared with tamoxifen.8–10 Accordingly, it has been 
generally assumed that these two nonsteroidal AIs are largely 
interchangeable with regard to efficacy and tolerability relative 
to tamoxifen; however, evidence suggests greater potency with 
letrozole compared with anastrozole.15,16 This review discusses 
the evidence for a greater potency of letrozole in aromatase 
inhibition, the apparent clinical correlates of this inhibition as 
gleaned from pivotal trials, and the design and undertaking 
of the Femara Anastrozole Clinical Evaluation (FACE) trial, 
specifically designed to resolve this issue unequivocally.
Initial adjuvant therapy: clinical 
evidence for efficacy differences 
between anastrozole and letrozole
The Arimidex Tamoxifen Alone  
or in Combination (ATAC) trial
The ATAC trial was originally designed to determine the 
efficacy and safety of initial adjuvant anastrozole (n = 3125), 
tamoxifen (n = 3116), or the two agents in combination 
(n = 3125) in PMW with early breast cancer.17 The trial was 
funded and implemented by the manufacturer of anastrozole. 
At the earliest analysis (median 33-month follow-up), it was 
determined that the combination arm was not significantly 
different from tamoxifen alone, and the arm was discontin-
ued with no further follow-up of this population of patients 
(n = 3125). DFS was defined in the trial as the time to local or 
distant recurrence, a new primary breast cancer, or death from 
any cause.17 Importantly, when the ATAC trial was initiated, 
hormone receptor-negative (HR−) or HR-unknown patients 
were not excluded from the trial; thus, only about 84% of 
the trial population was HR+ (n = 5216). In this   clinically 
important population, the hazard ratio (HR) for DFS was 
significantly greater in the anastrozole group (HR 0.78; 
95% confidence interval [CI]: 0.65−0.93; P = 0.002).17 At 
this first follow-up, a sufficient number of distant metastatic 
(DM) events had not occurred (n = 615 of 704 required); 
thus, the incidence of DM recurrence was not reported. 
Contralateral breast cancer (CLBC), however, was signifi-
cantly reduced in the HR+ population (odds ratio [OR] 0.29; 
95% CI: 0.13–0.64; P = 0.002).17 The difference in deaths 
between anastrozole and tamoxifen was small (n = 200 vs 
203 deaths, respectively), and thus an overall survival (OS) 
HR was not reported.
Subsequent analysis of the ATAC trial at a median 
68-month (5.7 years) follow-up confirmed the earlier 
findings, with a significant reduction in recurrence events 
in HR+ patients (Table 1).8 In this first analysis of DM 
events, a total of 699 had occurred (n = 324 anastrozole vs 
375 tamoxifen), and there was a significant improvement 
in the endpoint of time to distant recurrence (TTDR) with 
anastrozole relative to tamoxifen in the intent-to-treat (ITT) 
population (HR 0.86; 95% CI: 0.74−0.99; P = 0.04); how-
ever, in the HR+ population, TTDR was not significantly Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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improved (Table 1).8 Distant DFS (DDFS) was not a 
defined endpoint in the ATAC trial; however, as reported 
in the package insert, the difference in DDFS events was 
370 and 394 in the respective treatment groups in the HR+ 
population (HR 0.93; 95% CI: 0.80−1.07).18 As with the 
33-month analysis, significant improvement in CLBC was 
observed in the HR+ population. There were 831 deaths in 
the study at this early follow-up, and the HR for OS was 
not statistically different in either the ITT (HR 0.97; 95% 
CI: 0.85−1.12) or HR+ (Table 1) populations, despite a 
12% reduction in breast cancer-related deaths (HR 0.88; 
95% CI: 0.74–1.05; P = 0.2).8,18
Results of the ATAC trial have been reported up to the 
100-month (8.3 year) follow-up, at which time patients had 
received a mean of 4.11 and 3.97 years of anastrozole and 
tamoxifen treatment, respectively, with a high rate of compli-
ance with randomized treatment (88% and 87% of allocated 
treatment received before recurrence, respectively).7 In the 
HR+ population, significant improvement was observed in 
the endpoints of DFS (Table 1), time to recurrence (TTR; HR 
0.76; 95% CI: 0.67−0.87; P = 0.0001), and CLBC with anas-
trozole relative to tamoxifen (HR 0.60; 95% CI: 0.42−0.85; 
P = 0.004).7 Of note, there were 52 fewer TTDR events with 
anastrozole relative to tamoxifen at this time point, and this 
reached significance in the HR+ population (305 vs 357, 
Table 1). All cause death (472 vs 477 events, Table 1), death 
after recurrence (245 vs 269 events, HR 0.90; P = 0.2), 
and deaths without recurrence (227 vs 208 events, HR 
1.05; P = 0.6) were not significantly different in the HR+ 
population.
The Breast international  
Group (BiG) 1-98 trial
An important distinction between the BIG 1-98 trial and the 
ATAC trial is that BIG 1-98 was conducted in an independent 
manner by the International Breast Cancer Study Group, a 
large cooperative group responsible for study design, data 
collection, management, medical review, data analysis, and 
reporting.9 The unique design of BIG 1-98 allowed for the 
assessment of two adjuvant treatment strategies. The first 
compared initial adjuvant letrozole with tamoxifen for 5 
years’ total treatment, while the second compared the use 
of letrozole and tamoxifen, in either order, for a 2- and 
3-year treatment period, respectively, to complete a 5-year 
hormonal adjuvant treatment course in PMW with HR+ 
breast cancer.9 The Primary Core Analysis (PCA) compared 
all patients assigned to initial adjuvant letrozole (n = 4003) 
or tamoxifen (n = 4007), thus including patients assigned to 
sequential therapy for the first 2 years, on either letrozole 
or tamoxifen, while the monotherapy analysis compared 
only those patients who were assigned to the monotherapy 
(tamoxifen or letrozole) arms.
The ATAC and BIG 1-98 trials also differed significantly 
with respect to the definition of DFS. As noted earlier, ATAC 
defined a DFS event as local or distant recurrence, new 
primary breast cancer, or death from any cause,17 whereas 
Table 1 A comparison of key efficacy outcomes in the ATAC and BIG 1-98 trials7–12
Parameters ATACa 
(N = 5216)
ATACa 
(N = 5216)
BIG 1-98 
(N = 8010)
BIG 1-98 
(N = 8010)
BIG 1-98b 
(N = 4922)
BIG 1-98b 
(N = 4922)
Median follow-up 68 months 100 months 25.8 months 60.5 months 51 months 76 months
HR for DFS
P value
Risk reduction
HR 0.83
P = 0.005
17%
HR 0.85
P = 0.003
15%
HR 0.81
P = 0.003
19%
HR 0.86
P = 0.008
14%
CeN: HR 0.83
c 
17%c
HR 0.82
P = 0.007
18%
HR 0.88
P = 0.03
12%
CeN: HR 0.84c 
16%c
HR for TTDR
P value
Risk reduction
HR 0.84
P = 0.06
16%
HR 0.84
P = 0.022
16%
HR 0.73
P = 0.001
27%
HR 0.79
P = 0.003
21%
CeN: HR 0.78c 
22%
c
HR 0.81
P = 0.03
19%
HR 0.85
P = 0.05
15% 
CeN: HR 0.81c 
19%c
HR for OS
P value
Risk reduction
HR 0.97
P = 0.7
3%
HR 0.97
P = 0.7
3%
HR 0.86
P = 0.16
14%
HR 0.87
P = 0.07
13%
CeN: HR 0.81c 
19%c
HR 0.91
P = 0.35
9%
HR 0.87
P = 0.08
13%
CeN: HR 0.81 
19%
Notes: aResults are for the hormone receptor-positive patient population of ATAC; bResults for monotherapy arms of BiG 1-98; cexcludes 619 patients who crossed over 
to letrozole treatment arm after unblinding of tamoxifen treatment arm; HR and percent risk reduction are shown.
Abbreviations: ATAC, Arimidex Tamoxifen Alone or in Combination; BiG, Breast international Group; CeN, censored analysis; DFS, disease-free survival; HR, hazard 
ratio; OS, overall survival; TTDR, time to distant recurrence.Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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BIG 1-98 included the occurrence of a second, nonbreast 
cancer in its definition and also added an additional end-
point of DFS excluding a second, nonbreast cancer, similar 
to ATAC.9 Median follow up for the PCA was 25.8 months 
(2.2 years); at this time, both DFS (as defined in BIG 1-98, 
Table 1) and DFS excluding a second, nonbreast cancer 
(HR 0.79; 95% CI: 0.68−0.92; P = 0.002) were significantly 
improved with letrozole relative to tamoxifen.9 TTR (HR 
0.72; 95% CI: 0.61−0.86; P , 0.001) also was significantly 
improved with letrozole, and importantly, TTDR at this early 
time point was improved by 27% with letrozole (184 vs 249 
events, Table 1). There was no significant difference between 
the treatment groups in OS (166 vs 192 events, Table 1) at 
the time of this analysis.
In a subsequent, predefined analysis of BIG 1-98 in 
patients randomized to the monotherapy arms (n = 2463 letro-
zole, n = 2459 tamoxifen), median follow-up was approxi-
mately double that of the PCA, at 51 months (4.3 years).10 
At this time, there were 352 DFS events in the letrozole arm, 
compared with 418 events in the tamoxifen arm (Table 1); 
TTR (231 vs 291 events, HR 0.78; 95% CI: 0.65−0.92; 
P = 0.004) as well as TTDR (193 vs 234 events, Table 1) 
remained significantly improved with letrozole over tamox-
ifen in this analysis.10 Again, there were fewer overall deaths 
with letrozole versus tamoxifen (194 vs 211 events, Table 1), 
but the difference did not reach significance.
The pivotal results from the first PCA at 25.8 months led 
to a decision by the International Breast Cancer Study Group 
to unblind the tamoxifen arm of the trial (with all other arms 
remaining blinded), inform patients of the superiority of 
letrozole, and allow the selective crossover of patients from 
tamoxifen to letrozole treatment.11,12 In total, 619 patients, 
or 25.2% from the tamoxifen arm, elected to cross over to 
letrozole therapy, and most patients did so between years 
3 and 5 of the trial. Of note, the crossover did not signifi-
cantly affect results of the 51-month monotherapy analysis; 
however, subsequent comparisons between the letrozole and 
tamoxifen arms in the PCA and monotherapy populations, 
as detailed below, were affected.
In late 2008, extended follow-up for patients random-
ized to the monotherapy arms (n = 2463 letrozole, n = 2459 
tamoxifen), at a median follow-up of 76 months (6.3 years), 
was reported. All patients had completed protocol treatment 
at the time of this predefined, 10-year analysis.11 In the ITT 
population, despite the above-noted crossover of about a 
quarter of patients, DFS was significantly improved in the 
letrozole arm (509 events) compared with the tamoxifen arm 
(565 events) (Table 1). Specifically, letrozole monotherapy 
resulted in fewer breast cancer events (321 vs 363) and 
fewer second, nonbreast malignancies (101 vs 115). Similar 
improvements within the letrozole arm occurred for TTDR 
compared with the tamoxifen arm (257 vs 298, Table 1). 
Importantly, there was a pronounced trend in favor of letro-
zole in OS compared with tamoxifen. There were 40 fewer 
deaths in the letrozole treatment arm versus the tamoxifen 
arm (303 vs 343, Table 1). In addition, the number of deaths 
without a prior cancer event was the same in both treat-
ment groups (87 vs 87). As the crossover likely affected the 
comparison between the letrozole and tamoxifen groups, an 
exploratory analysis censoring events at the time of crossover 
was conducted. This analysis showed a greater and significant 
benefit of letrozole in all endpoints, including DFS, OS, and 
TTDR (Table 1).11 Additionally, an analysis called the inverse 
probability of censoring weighting was performed to handle 
bias created by censoring events and assess the true benefits 
of each treatment regimen. The results showed significant 
benefits with letrozole in DFS (HR 0.85; 95% CI: 0.76−0.96) 
and OS (HR 0.83; 95% CI: 0.71−0.97), with HRs residing 
between the results of the ITT and censored analyses.11 These 
data show an emerging survival benefit for patients treated 
with letrozole monotherapy over time.
Results presented in early 2009 also have detailed findings 
in the larger PCA population of BIG 1-98 (N = 8010) at the 
predefined, 10-year update (median 60.5 month follow-up).12 
As with the monotherapy analysis, despite the crossover of 
patients from tamoxifen to letrozole, there was a significant 
benefit of letrozole over tamoxifen in DFS (585 vs 664 
events, Table 1), TTR (368 vs 441 events, HR 0.82; 95% 
CI: 0.71−0.94; P = 0.004), and TTDR (287 vs 357 events, 
Table 1), and a strong trend in OS favoring letrozole (330 vs 
374 events, Table 1). In the exploratory censored analysis, 
the benefit of letrozole over tamoxifen was again greater and 
significant for all endpoints, including DFS, TTR, TTDR, 
and OS (Table 1).12 Results from the PCA population thus 
confirmed the findings of the monotherapy analysis, showing 
the emergence of a survival benefit over time with letrozole 
treatment.
ATAC and BiG 1-98: key  
efficacy differences
Several important subgroups of breast cancer patients can be 
identified. One of the most important subgroups comprises 
patients with lymph node involvement (ie, node positive 
[N+]), as they typically are more prone to early recurrence 
compared with node-negative (N0) patients (Figure 1).19,20 
Results of both the PCA (HR 0.71; 95% CI: 0.59−0.85; Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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P , 0.001) and the monotherapy analysis of BIG 1-98 
(HR 0.77; 95% CI: 0.64−0.92; P = 0.004) confirmed a sig-
nificant benefit of letrozole over tamoxifen for DFS in the 
subgroup of N+ patients (n = 3311 and n = 2067, respec-
tively). There also was a significant benefit of letrozole for 
patients with prior chemotherapy (PCA: n = 2024, HR 0.70; 
P = 0.01; monotherapy analysis: n = 1232, HR 0.74; P = 0.03) 
and in those with tumor size .2 cm (PCA: n = 2973, HR 
0.76; P = 0.004; monotherapy analysis: n = 1858, HR 0.79; 
P = 0.01).9,10 The updated results at 60.5 months from the 
PCA cohort also confirm a significant benefit of letrozole 
over tamoxifen in the subgroup of N+ patients (n = 3313) 
for both DFS (HR 0.79; 95% CI: 0.68–0.91) and OS (HR 
0.81; 95% CI: 0.67−0.97).12 In the ATAC trial, the DFS 
benefit also favored anastrozole in these important high-risk 
patient subgroups (N+: HR 0.84, tumors .2 cm: HR 0.74, 
prior chemotherapy: HR 0.89; P values were not reported 
at the 100-month analysis), and anastrozole benefits were 
maintained regardless of the use of prior chemotherapy or 
the type of chemotherapy.7,17,21
Comparison of the ATAC and BIG 1-98 trials also yields 
some important findings with respect to DM events, which 
have been associated with a greater risk of death overall 
as well as death due to breast cancer.22,23 In a retrospective 
analysis comparing the 33-month results from ATAC and 
the 25.8-month follow-up results from BIG 1-98 (as these 
first analyses represent the closest follow-ups between tri-
als), DFS efficacy of these two drugs versus tamoxifen was 
similar, but DM events were significantly lower with letrozole 
(relative risk [RR] 0.76; 95% CI: 0.63–0.92) compared with 
anastrozole (RR 0.87; 95% CI: 0.70–1.06).24 In addition, 
a trend toward improved OS was observed with letrozole 
in this analysis (RR 0.87; 95% CI: 0.71–1.06), arising pri-
marily from a significant reduction in deaths after a cancer 
event (RR 0.72; 95% CI: 0.57–0.92), whereas no such trend 
was observed in the ATAC trial.24 A retrospective analysis, 
focused specifically on early recurrence events occurring in 
BIG 1-98 (at 2 years), found a 30% reduction in early DM 
events with letrozole (87 vs 125 events, 2.3% vs 3.3%).25,26 
A similar unpublished retrospective analysis of early events 
in the ATAC trial revealed a comparatively smaller reduction 
in early DM events with anastrozole; distant recurrence at 
2.5 years was reduced by 7% (133 events vs 143 events) with 
anastrozole relative to tamoxifen in the ITT population.26,27 
A recently reported retrospective analysis of the HR+ sub-
group (n = 5216) in ATAC at 2 years showed a 21% relative 
reduction in DM events (HR 0.79; 95% CI: 0.58–1.07) with 
anastrozole that was not significant, compared with a 32% 
relative reduction in overall recurrences, which was signifi-
cant (HR 0.68; 95% CI: 0.52–0.88).28 In an earlier report, 
Rugo et al used a number needed to treat (NNT) analysis to 
compare early recurrence results from ATAC and BIG 1-98.29 
In this analysis, a lower NNT would indicate the more effica-
cious drug in preventing a given recurrence event (meaning 
fewer numbers of patients needing to be treated with that 
agent to prevent 1 recurrence). The results showed a major 
advantage of letrozole over anastrozole in the prevention of 
DM events (NNT = 100 for letrozole vs 300 for anastrozole). 
By comparison, anastrozole showed a slight advantage in 
terms of local and regional recurrences (NNT = 279 vs 423) 
as well as CLBC (NNT = 156 vs 948), although it should be 
noted that the number of these latter recurrence events was 
far smaller at the early follow-up, and the study did not take 
into account recently reported early recurrence results from 
ATAC in the HR+ subgroup.28,29 Interestingly, both drugs 
were nearly identical for preventing DFS events (ie, recur-
rences overall), with an NNT of 77 for anastrozole versus 
75 for letrozole.
Taken together, these findings suggest a meaningful ben-
efit of letrozole over anastrozole in reducing early DM events, 
and the significance of this reduction should not be underes-
timated. In a recently published study (N = 3614 PMW with 
operable, estrogen receptor-positive breast cancer receiving 
adjuvant tamoxifen), a peak of recurrence was reported at 
2 years (4.3% per annum), and DM events were found to be 
the predominant type of early recurrence event at this peak 
(3.4% per annum).30 Retrospective analyses from the ATAC 
and BIG 1-98 trials also confirmed that DM events constitute 
the majority of recurrence events at 2 years.25,28 Prevention 
of DM recurrence is thus a key factor in improving survival 
and reducing death from breast cancer.22,23
In light of the survival benefit with letrozole over tamox-
ifen, which has been seen in the later follow-ups of both the 
PCA and monotherapy cohorts,11,12 a recent study examined 
the NNT to save a life with anastrozole and letrozole.31 
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This analysis was based on data from the 68-month follow-up 
of ATAC (3% improvement in OS) and the 76-month follow 
up of the monotherapy arms of BIG 1-98 (censored analysis, 
19% improvement in OS). The NNT to avoid one early distant 
recurrence was significantly lower with letrozole versus anas-
trozole (100 vs 303, threefold difference), as was the NNT 
required to avoid one death (63 vs 161, 2.5-fold difference). 
The investigators speculated that the difference in the reduc-
tion of early DM events with letrozole versus anastrozole 
could account for the latter difference in deaths.31 It also 
should be noted that the magnitude of the survival benefit 
seen with letrozole over tamoxifen, as expressed in terms 
of NNT, is comparable with that seen with other paradigm-
changing adjuvant regimens (eg, the addition of taxanes to 
anthracycline-based chemotherapy regimens).32
Binding and potency  
of anastrozole and letrozole
The potency of AIs relates to their ability to specifically 
suppress the enzyme aromatase, and in this regard, the 
third-generation AIs including letrozole and anastrozole 
demonstrate clear advantages over first-generation com-
pounds such as aminoglutethimide. In an early, open-label, 
randomized, comparative trial of letrozole (n = 185, 2.5 mg 
letrozole; n = 192, 0.5 mg letrozole) with aminoglutethimide 
(n = 178) in women with advanced breast cancer, letrozole at 
2.5 or 0.5 mg resulted in an objective response rate (ORR) 
of 19.5% and 16.7%, respectively, versus only 12.4% for 
aminoglutethimide, and there was a significantly better time 
to progression (RR 0.72; 95% CI: 0.57–0.92; P = 0.008), time 
to treatment failure (RR 0.70; 95% CI: 0.55–0.88; P = 0.003), 
and OS (RR 0.64; 95% CI: 0.49–0.85; P = 0.002) for letro-
zole 2.5 mg versus aminoglutethimide.33 Another study of 
advanced breast cancer patients compared letrozole (n = 356) 
with anastrozole (n = 357) as second-line therapy.34 In this 
study, median time to progression, the primary endpoint, was 
identical for the two drugs (5.7 months). However, ORR was 
significantly improved with letrozole relative to anastrozole 
(19.1% vs 12.3%, P = 0.013).34 It is unclear whether these 
differences in clinical efficacy are directly correlated with 
the degree of aromatase inhibition and the corresponding 
suppression of plasma E2; however, it is notable that the 
potency of aminoglutethimide in this regard (90.6% sup-
pression) is substantively lower than that of letrozole (nearly 
99% suppression).6,35,36
Although both anastrozole and letrozole are nonsteroidal 
AIs, there are important differences between these 
two   compounds, which could, in part, underlie the clini-
cal results that have been observed. Computer-assisted 
molecular modeling studies suggest that letrozole fits very 
tightly into the binding site of the aromatase enzyme and 
occupies the entire binding site, whereas anastrozole does 
not (Figure 2).4,37 In a recent study, plasma samples from a 
neoadjuvant study using letrozole (16 weeks’ neoadjuvant 
treatment followed by surgery) were directly compared with 
samples from a similar neoadjuvant trial of anastrozole using 
a highly sensitive assay for E2 detection.15 The authors found 
a significant difference in the degree of plasma E2 suppression 
for letrozole versus anastrozole (95.2% vs 92.8%, P = 0.018), 
and there were similar, significant differences observed for 
estrone (98.8% vs 96.3%, P = 0.003) and estrone sulfate 
(98.9% vs 95.3%, P = 0.003).15 The suppression of plasma 
E2 by these two AIs also has been directly compared in the 
ALIQUOT (Anastrozole versus Letrozole, an Investigation 
of Quality Of Life and Tolerability) trial. This study com-
pared outcomes following 3 months of adjuvant treatment 
with letrozole or anastrozole in a randomized crossover 
design in 54 PMW with HR+ breast cancer.16 Patients were 
randomized to letrozole for 12 weeks followed by anastro-
zole for 12 weeks (n = 27), or the reverse sequence (n = 27), 
and plasma levels of E2 were assayed following each drug 
treatment   (Figure 3a). Significantly fewer patients had E2 
plasma values of 3 pmol/L or greater (Figure 3b), the percent 
residual E2 level was lower (Figure 3c), and the mean plasma 
E2 level after extrapolation was significantly lower following 
letrozole versus anastrozole treatment (Figure 3d).16 These 
results were consistent regardless of which agent was given 
first in the study and regardless of prior tamoxifen use. Sup-
Anastrozole Letrozole
Figure  2  Binding  of  nonsteroidal  aromatase  inhibitors  anastrozole  and  letrozole. 
Computer-assisted molecular modeling displaying the active site fit and heme group 
binding in the aromatase enzyme. whereas the distal portion of the letrozole molecule 
fits tightly and occupies the entire binding site, the same is not true for anastrozole.4,37 
Reprinted  with  permission  from  Mouridsen  HT,  Bhatnagar  AS.  Letrozole  in 
the  treatment  of  breast  cancer.  Expert  Opin  Pharmacother.  2005;6:1389–1399.4 
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explanation for their differences in the clinical setting. It 
is quite plausible that lower plasma E2 levels afforded by 
letrozole treatment provide for more complete eradication of 
micrometastatic tumor deposits, which could in turn result 
in fewer DM recurrences.26
FACE: trial design and methods
As outlined above, there is evidence from clinical and 
pharmacodynamic data to suggest a difference in potency 
between the nonsteroidal AIs anastrozole and letrozole. 
Nevertheless, the clinical data presented herein admittedly 
are from different trials (ATAC and BIG 1-98) that were 
conducted at different times and with different overall goals, 
and with substantive differences in study design, population, 
and follow-up reporting of results. Accordingly, only limited 
conclusions can be drawn from such indirect comparisons. 
More meaningful comparisons between agents ideally 
should come from head-to-head trails. The FACE trial was 
designed with the caveats of cross-trial comparisons in mind, 
and   forthcoming results will begin to address the important 
issue of efficacy and safety differences between the third-
generation AIs. FACE was designed as a head-to-head, 
Phase III, open-label, randomized, multicenter (up to 
250 international sites) clinical trial comparing adjuvant 
treatment with anastrozole (1 mg daily) or letrozole (2.5 mg) 
in more than 4000 PMW with HR+ and N+ breast cancer.38,39 
As of March 2008, accrual into the trial was completed, with 
4172 patients enrolled. Consequently, safety and efficacy 
interim data are imminent. Patients who were N+ were spe-
cifically chosen for FACE, as these women are known to be 
at a higher overall relapse risk19,20 and are prone to earlier 
recurrence (within 2 years).25 These women would therefore 
benefit the most from initial adjuvant therapy with an AI, 
as opposed to initial tamoxifen therapy. In addition, such a 
patient population could theoretically allow for a statistical 
difference in efficacy between these AIs to emerge in a shorter 
period of time. Treatment was to commence following stan-
dard chemotherapy or radiotherapy (if given), and patients 
were to receive treatment for up to 5 years, or until disease 
recurrence/relapse. Patients were to be stratified according to 
the number of involved nodes, as well as human epidermal 
growth factor receptor 2 status.38,39
The primary endpoint of FACE is DFS at 5 years for 
letrozole and anastrozole, with the important additional 
secondary endpoints of OS, TTDR, time to CLBC, and 
safety. The safety results also will be particularly impor-
tant to determine any potential differences between these 
N = 27
N = 27
Assay Assay
Crossover
LET LET
ANA ANA
A
12 weeks 12 weeks
Assay
Figure  3  A)  Study  design  of  ALiQUOT  (Anastrozole  versus  Letrozole,  an 
investigation of Quality Of Life and Tolerability), an open-label, crossover study 
comparing  adjuvant  therapy  with  letrozole  and  anastrozole.  Postmenopausal 
women with hormone receptor-positive breast cancer (n = 27 per group) were 
randomized to 3 months’ treatment with letrozole (LeT) followed by anastrozole 
(ANA), or the reverse sequence; plasma estrogen (e2) levels were assayed at the 
indicated time points. B) Percent of patients with an e2 value of 3 pmol/L or greater 
following treatment with LET or ANA; the difference was statistically significant. 
C) Mean residual e2 level (%) following treatment with LeT or ANA. D) Mean e2 
level in pmol/L after extrapolation following treatment with either LeT or ANA; the 
difference was statistically significant.16
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pression of estrogen in the breast tumor tissue also has been 
found to be more pronounced following neoadjuvant letrozole 
  compared with anastrozole. Mean percentages of suppres-
sion with letrozole and anastrozole were 97.6% and 89.0% 
for E2, 90.7% vs 83.4% for estrone, and 90.1% vs 72.9% for 
estrone sulfate, respectively.15 Collectively, these findings 
provide evidence for a greater inhibition of aromatase and a 
greater corresponding suppression of plasma and tissue E2 
levels with letrozole relative to anastrozole, and a possible Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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AIs with respect to bone health and cardiovascular adverse 
events. The trial is sufficiently powered to detect a   difference 
of 3.5% between the two treatment arms at 5 years (ie, 5 
years’ DFS of 76.5% for anastrozole vs 80.0% for letrozole); 
this   corresponds to an HR of 0.83 in favor of letrozole. 
Interim efficacy analyses for DFS also are planned when 
approximately a third of the maximum number of events 
have occurred, and again when about two-thirds of the 
maximum events have occurred (about 320 and 639 events, 
respectively). Finally, a number of correlative science studies 
will be undertaken in FACE. These include an assessment of 
E2 suppression during treatment with anastrozole or letro-
zole, and the use of exploratory proteomics and genomics 
studies to identify differential protein, blood metabolite, 
and/or gene expression profiles, if any, that are associated 
with differential DFS and OS with anastrozole or letrozole 
therapy. As with BIG 1-98, the data will be provided by an 
independent academic organization, the Michelangelo Foun-
dation, and will be reviewed in a confidential manner by an 
Independent Data Monitoring Committee (IDMC) chaired 
by Dr H Rugo; the IDMC will make recommendations 
to the Trial Steering Committee,   co-chaired by Professor 
I Smith and Dr J O’Shaughnessy. The Steering Committee 
has developed a publication plan, and will determine when 
abstracts and/or manuscripts originating from the trial will 
be developed and presented. At annual intervals, and at the 
time of the interim analyses, the validated database will 
be transferred to the   Michelangelo Foundation, which will 
work closely with the IDMC to monitor the study. Only after 
the final analysis has been completed will the database be 
transferred to the study   sponsor, Novartis.
Conclusions
Evidence from the pivotal trials of anastrozole and letro-
zole, ATAC and BIG 1-98, has revealed important efficacy 
differences between these two drugs (Table 1), particularly 
in the prevention of early DM events, which are by far the 
most prevalent and the most deadly types of breast cancer 
recurrence events.22,23,25,27,28,30 Differences in the binding of 
letrozole and anastrozole to the aromatase enzyme (Fig-
ure 1), and their corresponding inhibitory activity, may in 
part underlie the more complete suppression of E2 levels 
with letrozole versus anastrozole that has been observed in 
directly comparative clinical studies such as ALIQUOT (Fig-
ure 3). It is plausible that the more complete suppression of 
E2 in plasma and tissues by letrozole in turn causes a greater 
eradication of distant micrometastatic breast cancer deposits, 
which can develop later into fulminant DM recurrences. This 
especially may be relevant for patients with N+ disease, as 
these patients present a greater risk for early recurrence 
(Figure 2). Although letrozole effectively suppresses recur-
rence in all relevant patient subgroups, its benefit is especially 
pronounced in the high-risk subgroup of N+ patients.9,10 
In addition, while not reported in the 76-month follow-up 
of the monotherapy arms, subgroup analysis in the PCA 
population at 60.5 months shows a significant DFS and OS 
benefit in the N+ subgroup, despite the crossover of about 
25% of patients from tamoxifen to letrozole.12
There is precedent for an association between a lower 
degree of aromatase inhibition (ie, in the case of aminoglu-
tethimide) and poorer outcomes compared with letrozole 
in advanced cancer patients.33 Despite these observations, 
however, comparisons with anastrozole remain indirect, 
and only directly comparative head-to-head trials will be 
useful in resolving the question of potential efficacy differ-
ences between letrozole and anastrozole. The development 
and design of the FACE trial undoubtedly will provide a 
conclusive resolution to this question, and demonstrate 
unequivocally which AI is more appropriately used upfront 
in the high-risk population of N+ breast cancer patients. 
It is hoped that other similarly designed trials will be 
implemented to enable further comparisons among the 
third-  generation AIs in different patient populations and 
treatment settings. In this regard, the National Cancer 
Institute of Canada MA. 27 trial is investigating upfront 
anastrozole versus exemestane in the adjuvant setting in 
PMW with HR+ breast cancer.40 Analysis of the trial is 
forthcoming; to date, 6830 patients have been accrued. 
Until the results of this trial and the FACE trial are reported, 
however, clinicians need to rely on the available clinical 
evidence, which strongly favors the use of upfront letrozole 
for PMW with HR+ early breast cancer.
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